XNCR - Xencor Inc logo

XNCR

Xencor Inc

Xencor Inc is a clinical-stage biopharmaceutical company that develops engineered monoclonal antibodies for cancer and autoimmune diseases. Its pipeline includes treatments for conditions like renal cell carcinoma, ovarian cancer, and rheumatoid arthritis.

โš•๏ธ Healthcare NASDAQ Listed 2013 $ USD
$1,000 invested 10 years ago โ†’$1,042today

Score Overview

1 Year
Score
Net Growth-77.68%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growth-57.20%
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Score1.8
Net Growth-297.66%
Net Trend20%
Net Income Consistencyโ€”
Rev Growth-80.46%
Rev Trend40%
Revenue Consistencyโ€”
10 Years
Score
Net Growth-6x
Net Trend30%
Net Income Consistency
Rev Growth-38.58%
Rev Trend50%
Revenue Consistency
All Time
Score
Net Growth-171.04%
Net Trend38%
Net Income Consistency
Rev Growth428.43%
Rev Trend54%
Revenue Consistency

See the full market ranking โ†’

Xencor Inc fundamental performance

Between 2020 and 2025, revenue grew from $ 122M to $ 125M and net income went from -$ 63M to -$ 91M. Revenue increased in 2 of those 5 years; net income in 1.

Across Xencor Inc's full reported history, from 2013 to 2025, revenue grew from $ 10M to $ 125M and net income went from -$ 60M to -$ 91M. Revenue increased in 54% of the years measured; net income in 38%.

Xencor Inc currently holds a 5-year HDB Score of 1.8 out of 10. How the HDB Score is calculated.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 23.18โ€”
1 Year2025-08-12
$ 7.75199.10%
5 Years2021-08-12
$ 31.89-27.31%
10 Years2016-08-12
$ 22.254.18%
All Time2013-12-03
$ 8.34177.94%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 53M-$ 163M$ 377M
2025$ 125M-$ 91M$ 547M
2024$ 110M-$ 232M$ 497M
2023$ 168M-$ 126M$ 593M
2022$ 164M-$ 55M$ 623M
2021$ 275M$ 82M$ 334M
2020$ 122M-$ 63M$ 603M
2019$ 156M$ 26M$ 527M
2018$ 40M-$ 70M$ 294M
2017$ 35M-$ 48M$ 224M
2016$ 87M$ 23M$ 130M
2015$ 27M-$ 17M$ 96M
2014$ 9M-$ 16M$ 54M
IPO2013$ 10M-$ 60M$ 77M

Explore beyond XNCR

You're looking at Xencor Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies